Tenex Health's TenJet device shows strong clinical performance in a six-month study, potentially accelerating commercial adoption for the minimally invasive treatment of gluteal tendinopathy.
The positive clinical data from the multicenter research study validates the efficacy of the TenJet device in treating recalcitrant gluteal tendinopathy. By demonstrating significant pain reduction and functional improvement at the six-month mark, the company strengthens its clinical value proposition, which is expected to drive broader physician adoption and enhance investor confidence in the device's commercial potential.
The device is used in a minimally invasive, ultrasound-guided procedure to treat recalcitrant gluteal tendinopathy.
The study reported significant pain reduction and improved function at the six-month follow-up mark.
Tenex Health announced successful multicenter research results demonstrating that its TenJet device significantly reduces pain and improves function in patients with recalcitrant gluteal tendinopathy. The six-month study data supports the clinical efficacy of the minimally invasive, ultrasound-guided procedure.
The multicenter research indicates that the TenJet device provides significant pain relief and improved physical function for patients suffering from recalcitrant gluteal tendinopathy over a six-month period.